PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 66 | 3 | 57–62
Article title

Pentraxyna 3 – nowy wskaźnik w ocenie procesu miażdżycowego

Content
Title variants
EN
Pentraxin 3 – a new marker in the assessment of atherosclerosis
Languages of publication
PL
Abstracts
EN
Atherosclerosis is a medical problem of high prevalence being a main cause of cardiovascular diseases. Outcomes of many experimental and clinical studies have confi rmed that infl ammation plays an important role in atherogenesis. One of infl ammatory markers, acute phase protein produced in response to infl ammatory signals, among others by several type of cells in atherosclerotic plaques, is pentraxin 3 (PTX3). On the basis of outcomes of performed studies it is supposed that PTX3 may become a new indicator useful for detecting diseases of atherosclerotic origin on their very early stages of development what may enable the implementation of treatment to prevent their progression.
PL
Miażdżyca jest powszechnym problemem zdrowotnym, stanowiącym główną przyczynę chorób układu sercowo-naczyniowego. Wyniki wielu eksperymentów i badań klinicznych potwierdzają, że w procesie jej rozwoju ważną rolę odgrywa stan zapalny. Jednym z markerów zapalenia, białkiem ostrej fazy produkowanym w odpowiedzi na mediatory stanu zapalnego, m.in. przez komórki budujące blaszkę miażdżycową, jest pentraxyna 3. Na podstawie wyników przeprowadzonych badań przypuszcza się, że białko to może okazać się ważnym wczesnym wskaźnikiem rozwoju i zaawansowania zmian miażdżycowych, a tym samym stać się nowym markerem przydatnym do wykrywania chorób na podłożu miażdżycy we wczesnych etapach ich rozwoju, umożliwiając wdrożenie leczenia zapobiegającego ich progresji.
Discipline
Publisher

Year
Volume
66
Issue
3
Pages
57–62
Physical description
Contributors
  • Wielospecjalistyczny Szpital Powiatowy im. dr Hagera w Tarnowskich Górach
  • Klinika Chorób Wewnętrznych, Diabetologii i Nefrologii Wydziału Lekarskiego z Oddziałem Lekarsko-Dentystycznym w Zabrzu Śląskiego Uniwersytetu Medycznego w Katowicach ul. 3 Maja 13–15 tel.32 370 44 15 41-800 Zabrze, jgumprecht@sum.edu.pl
References
  • 1. Faxon D.P., Fuster V., Libby P. et al. Atherocslerotic Vascular Disease Conference: group III; patophysiology. Circulation 2004; 109: 2617–2625.
  • 2. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome – a new worldwide defi nition. Lancet 2005; 366: 1059–1062.
  • 3. Ross R. Atherosclerosis – an infl ammatory disease. N. Engl. J. Med. 1999; 340: 115–126.
  • 4. Jylhävä J., Haarala A., Kähönen M. et al. Pentraxin 3 (PTX3) is associated with car- diovascular risk factors: the Health 2000 Survey. Clin. Exp. Immunol. 2011; 164: 211–217.
  • 5. Bottazzi B., Garlanda C., Salvatori G. et al. Pentraxins as a key component of in- nate immunity. Curr. Opin. Immunol. 2006; 18: 10–15.
  • 6. Mantovani A., Garlanda C., Bottazzi B. et al. The long pentraxin PTX3 in vascular pathology. Vascul. Pharmacol. 2006; 45: 326–330.
  • 7. Bottazzi B., Vouret-Craviari V., Bastone A. et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and diff erences with the short pentraxins C-reactive protein and serum amyloid P component. J. Biol. Chem. 1997; 272: 32817–32823.
  • 8. Bottazzi B., Garlanda C., Cotena A. et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: in- terplay with cellular innate immunity. Im- munol. Rev. 2009; Vol. 227: 9–18.
  • 9. Han B., Mura M., Andrade C.F. et al. TNF alpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J. Immunol. 2005; 175: 8303–8311.
  • 10. Willeke F., Assad A., Findeisen P. et al. Overexpression of a member of the pen- traxin family (PTX3) in human soft tis- sue liposarcoma. Eur. J. Cancer. 2006; 42: 2639–2646.
  • 11. Peri G., Introna M., Corradi D. et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarc- tion in humans. Circulation 2000; 102: 636–641.
  • 12. Salio M., Chimenti S., De Angelis N. et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarc- tion. Circulation 2008; 117: 1055–1064.
  • 13. Matsui S., Ishii J., Kitagawa F. et al. Pen- traxin 3 in unstable angina and non-ST- -segment elevation myocardial infarction. Atherosclerosis 2010; 210: 220–225.
  • 14. Matsubara J., Sugiyama S., Nozaki T. et al. Pentraxin 3 is a new infl ammatory marker correlated with left ventricular dia- stolic dysfunction and heart failure with normal ejection fraction. J. Am. Coll. Car- diol. 2011; 57: 861–869.
  • 15. Garlanda C., Hirsch E., Bozza S. et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune re- sponse. Nature 2002; 420: 182–186.
  • 16. Reading P.C., Bozza S., Gilbertson B. et al. Antiviral activity of thelong chain pentraxin PTX3 against infl uenza viruses. J. Immunol. 2008; 180: 3391–3398.
  • 17. Napoleone E., di Santo A., Bastone A. et al. Long pentraxin PTX3 upregulates tissue factor expression in human endo- thelial cells: a novel link between vascular infl ammation and clotting activation. Ar- terioscler. Thromb. Vasc. Biol. 2002; 22: 782–787.
  • 18. Napoleone E., di Santo A., Peri G. et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: an- other link between infl ammation and clot- ting activation. J. Leukoc. Biol. 2004; 76: 203–209.
  • 19. Norata G.D., Marchesi P., Venu V. et al. Defi ciency of the long Pentraxin PTX3 Pro- motes Vascular Infl ammation and Athero- sclerosis. Circulation 2009; 120; 699–708. 20. Rolph M.S., Zimmer S., Bottazzi B. et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Ar- terioscler. Thromb. Vasc. Biol. 2002; 22: e10–e14.
  • 21. Mallat Z., Tedgui A. HDL, PTX3, and vascular protection. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 809–811.
  • 22. Psaty M., Jenny N.S., Alice M. et al. The Cardiovascular Health Study Associa- tions of Pentraxin 3 With Cardiovascular Disease and All-Cause Dead. Arterioscler. Thromb. Vasc. Biol. 2009; 29; 594–599.
  • 23. Zanetti M., Bosutti A., Ferreira C. et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical ath- erosclerosis: evidence for association with atherogenic lipid profi le. Clin. Exp. 2009; 9: 243–248.
  • 24. Ohbayashi H., Miyazawa C., Miyamoto K. et al. Pitavastatin improves plasma pen- traxin 3 and arterial stiff ness in atheroscle- rotic patients with hypercholesterolemia. J. Atheroscler. Thromb. 2009; 16: 490– –500.
  • 25. Latini R., Maggioni A., Peri G. et al. Prognostic Signifi cance of the Long Pentraxin PTX3 in Acute Myocardial Infarction. Circulation 2004; 110; 2349–2354.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-6a1d6b40-220c-4cf2-b734-3b3a8937f80d
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.